Preferences of melanoma patients to accept adjuvant therapy and toxicity – a qualitative substudy of the GerMelaTox-A project
2024

Melanoma Patients' Preferences for Adjuvant Therapy

Sample size: 17 publication Evidence: moderate

Author Information

Author(s): Toni Maria Janke, Laura Moysig, Christine Blome, Katharina C. Kähler

Primary Institution: Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany

Hypothesis

What are personal motives for tolerating or rejecting adjuvant therapy and its side effects?

Conclusion

Patients in our study indicate high willingness to undergo adjuvant therapy, even when facing toxicity.

Supporting Evidence

  • Patients expressed a willingness to tolerate side effects for the chance of preventing cancer recurrence.
  • Participants emphasized the importance of maintaining quality of life while undergoing treatment.
  • Many patients preferred treatment options that would minimally disrupt their daily lives.

Takeaway

Patients with melanoma are willing to try treatments even if they might make them feel sick, because they hope it will help them live longer.

Methodology

Semi-structured interviews were conducted with a subsample of patients to investigate the underlying reasons for treatment decisions.

Potential Biases

The study may be influenced by recall bias as participants reflected on their past experiences with cancer.

Limitations

Participants were recruited at a single study center, which may not represent the broader patient population.

Participant Demographics

Mean age of participants was 55.5 years, with 12 females and 5 males.

Digital Object Identifier (DOI)

10.1007/s00432-024-06014-8

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication